⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2057684 | 0.91 | — | — | |
| SCHEMBL2057167 | 0.83 | — | — | |
| SCHEMBL8580513 | 0.78 | — | — | |
| SCHEMBL16232226 | 0.77 | — | — | |
| SCHEMBL14964623 | 0.77 | — | — | |
| SCHEMBL3459658 | 0.77 | — | — | |
| SCHEMBL12621545 | 0.77 | — | — | |
| SCHEMBL1807609 | 0.72 | — | — | |
| SCHEMBL12621538 | 0.72 | KDM4E (0.30) | — | |
| SCHEMBL20767781 | 0.69 | RECQL (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250325512-A1 | Neurodegenerative Disorders And Muscle Diseases Implicating Pufas | BIOJIVA LLC (US) | 2025-10-23 | — | — | US | disclosed |
| US-20220378734-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RTMFP ENTERPRISES INC. | 2022-12-01 | — | — | US | disclosed |
| US-11510888-B2 | Alleviating oxidative stress disorders with PUFA derivatives | RETROTOPE, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-RE49238-E1 | Alleviating oxidative stress disorders with PUFA derivatives | RETROTOPE, INC. (US) | 2022-10-11 | — | — | US | disclosed |
| US-20220304968-A1 | OXIDATIVE RETINAL DISEASES | BIOJIVA LLC | 2022-09-29 | — | — | US | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11241409-B2 | Neurodegenerative disorders and muscle diseases implicating PUFAs | RETROTOPE, INC. (US) | 2022-02-08 | — | — | US | disclosed |
| EP-2701698-B1 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE INC (US) | 2020-12-23 | — | — | EP | disclosed |
| EP-3730135-A1 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | Retrotope, Inc. (US) | 2020-10-28 | — | — | EP | disclosed |
| EP-3689342-A1 | OXIDATIVE RETINAL DISEASES | Retrotope, Inc. (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10052299-B2 | Alleviating oxidative stress disorders with PUFA derivatives | RETROTOPE, INC. (US) | 2018-08-21 | — | — | US | disclosed |
| US-20140147428-A1 | NEURODEGENERATIVE DISORDERS AND MUSCLE DISEASES IMPLICATING PUFAS | RETROTOPE, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20140050712-A1 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140050712-A1 | DISORDERS IMPLICATING PUFA OXIDATION | RETROTOPE, INC. (US) | 2014-02-20 | — | — | US | disclosed |
| US-20140044692-A1 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140044693-A1 | OXIDATIVE RETINAL DISEASES | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20140044692-A1 | IMPAIRED ENERGY PROCESSING DISORDERS AND MITOCHONDRIAL DEFICIENCY | RETROTOPE, INC. (US) | 2014-02-13 | — | — | US | disclosed |
| US-20110105609-A1 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES | RETROTOPE, INC. (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105609-A1 | ALLEVIATING OXIDATIVE STRESS DISORDERS WITH PUFA DERIVATIVES | RETROTOPE, INC. (US) | 2011-05-05 | — | — | US | disclosed |